Provider Briefing: Rosuvastatin Supply and Availability in 2026

Rosuvastatin remains one of the most widely prescribed statins in the United States, with tens of millions of prescriptions filled annually. As a cornerstone of dyslipidemia management and cardiovascular risk reduction, any disruption to its supply has direct implications for patient care and clinical workflows.

This briefing provides an evidence-based overview of Rosuvastatin's current supply status, prescribing considerations, cost landscape, and practical tools to help your patients maintain continuity of statin therapy.

Current Supply Status: Timeline and Context

As of February 2026, Rosuvastatin is not listed on the FDA Drug Shortage Database or the ASHP Drug Shortages Resource Center. There is no active national shortage.

Rosuvastatin Calcium has been available as a generic since July 2016, when the patent on Crestor (AstraZeneca) expired. Today, multiple manufacturers produce generic Rosuvastatin, including:

• Teva Pharmaceuticals
• Sandoz (Novartis)
• Aurobindo Pharma
• Zydus Pharmaceuticals
• Hikma Pharmaceuticals
• Amneal Pharmaceuticals

This multi-source manufacturing environment has kept the supply relatively stable. However, clinicians should be aware that localized stock-outs do occur, particularly for less commonly prescribed strengths (5 mg and 40 mg).

Historical Context

Unlike medications that have experienced significant national shortages (e.g., stimulants, certain antibiotics), Rosuvastatin has maintained a stable supply chain since generic entry. No significant ASHP-documented shortages have been reported for this medication.

Prescribing Implications

While the supply outlook is favorable, there are several prescribing considerations worth noting:

Dose-Specific Availability

The 10 mg and 20 mg strengths are the most commonly dispensed and are almost universally available. The 40 mg strength — reserved for patients who haven't achieved LDL goals on 20 mg — may have more limited availability at individual pharmacy locations due to lower stocking levels.

If a patient reports difficulty filling a 40 mg prescription, consider:

• Prescribing two 20 mg tablets as a bridge
• Directing the patient to a pharmacy with confirmed stock via Medfinder for Providers
• Utilizing mail-order pharmacy options

Formulation Considerations

In addition to standard tablets, Ezallor Sprinkle (rosuvastatin calcium) is available as a sprinkle capsule formulation. This may be appropriate for:

• Patients with dysphagia
• Patients receiving medication via feeding tubes
• Pediatric patients with heterozygous familial hypercholesterolemia (ages 7+)

Special Populations

Prescribers should be mindful of dose adjustments in specific populations:

• Asian descent: Higher systemic exposure; initiate at 5 mg
• Severe renal impairment (CrCl <30 mL/min): Do not exceed 10 mg daily
• Concomitant cyclosporine use: Maximum 5 mg daily
• Concomitant certain protease inhibitors: Maximum 10 mg daily

For complete drug interaction guidance, see our clinical reference: Rosuvastatin Drug Interactions.

Availability Picture: Where Patients Can Find Rosuvastatin

The multi-manufacturer generic landscape means Rosuvastatin is available at virtually all retail pharmacies. However, patient-reported difficulties in filling prescriptions often stem from:

• Chain pharmacy inventory algorithms that may under-stock certain strengths
• Insurance formulary changes that create delays at the pharmacy counter
• Patient confusion between availability issues and coverage issues

When a patient reports they "can't find" their Rosuvastatin, it's worth clarifying whether the issue is:

1. Physical stock-out at their preferred pharmacy
2. Insurance coverage or prior authorization barrier
3. Cost concerns (especially if previously on brand Crestor)

Cost and Access Landscape

Generic Rosuvastatin is among the most affordable statins on the market:

For commercially insured patients still on brand Crestor, AstraZeneca offers a savings card reducing copays to as low as $3 per 30-day supply (maximum savings $150 per fill). This is not available for government-insured patients.

The AstraZeneca Patient Assistance Program (AZ&Me) provides Crestor at no cost for qualifying uninsured patients meeting income criteria.

For a patient-facing resource on cost savings, direct patients to: How to Save Money on Rosuvastatin.

Tools and Resources for Your Practice

Several tools can help streamline medication access for your patients:

Medfinder for Providers

Medfinder offers real-time pharmacy stock data that can be integrated into patient counseling workflows. When a patient reports difficulty filling a prescription, you or your staff can quickly identify pharmacies with confirmed availability.

Electronic Prescribing Best Practices

• When e-prescribing, specify "generic Rosuvastatin" rather than brand Crestor to avoid formulary rejections and cost barriers
• Include "DAW 0" (Dispense as Written — substitution permitted) to allow pharmacists maximum flexibility
• Consider sending prescriptions to pharmacies with confirmed stock, especially for the 40 mg strength

Therapeutic Alternatives

If a patient cannot obtain Rosuvastatin and needs an immediate alternative, the following substitutions provide comparable LDL reduction:

• Atorvastatin 40 mg ≈ Rosuvastatin 20 mg (high-intensity)
• Atorvastatin 80 mg ≈ Rosuvastatin 40 mg (high-intensity)
• Simvastatin 40 mg — moderate-intensity option (note: more drug interactions)
• Pitavastatin 4 mg — moderate-intensity, potentially lower diabetes risk

Full alternative analysis: Alternatives to Rosuvastatin.

Looking Ahead

The Rosuvastatin supply outlook for 2026 remains positive. The multi-manufacturer generic market, combined with the medication's inclusion on most insurance formularies as a preferred generic, suggests continued stable availability.

Key developments to monitor:

• Combination products: Rosuvastatin/Ezetimibe fixed-dose combinations (e.g., Roszet) are gaining traction and may shift some prescribing patterns
• Guideline updates: The 2025 ACC/AHA guidelines continue to emphasize high-intensity statin therapy for acute coronary syndrome and ASCVD risk reduction
• Biosimilar PCSK9 inhibitors: May reduce statin burden for some high-risk patients, but statins remain first-line therapy

Final Thoughts

Rosuvastatin remains widely available, affordable, and an evidence-based cornerstone of cardiovascular risk management. While localized pharmacy stock-outs may occasionally inconvenience patients, the overall supply chain is robust.

Equipping your practice with tools like Medfinder for Providers and maintaining awareness of dose-equivalent alternatives can help ensure your patients maintain uninterrupted statin therapy — a critical factor in long-term cardiovascular outcomes.

For provider-specific guidance on helping patients locate medications, see: How to Help Your Patients Find Rosuvastatin in Stock.